Compare Hilton Hotels Corporation Common Stock (HLT) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Smith & Nephew plc — how do they compare? Hilton Hotels Corporation Common Stock trades at $325.6 (market cap $72.76B), while Smith & Nephew plc trades at $27.07 (market cap $11.10B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 6.6× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Hilton Hotels Corporation Common Stock for 138 Days and Smith & Nephew plc for 120 Days on average.
| HLT | SNN | |
|---|---|---|
Market Cap | $72.76B | $11.10B |
Volume | 1,148,634 | 1,051,703 |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $37.17 |
52-Week Low | $256.96 | $26.42 |
Typical Hold Time | 138 Days | 120 Days |
Enterprise Value | $85.78B | $14.13B |
Dividend Yield | 0.19% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $320.5, down 0.65% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $348.11. The company has consistently beaten earnings expectations in recent quarters, with Q3 2026 results expected soon. Revenue has grown steadily from $8.8B in 2022 to $12.04B in 2025, though net income margins have fluctuated. Recent news highlights institutional buying and positive travel trends for 2027.
The outlook for HLT is positive, supported by strong earnings performance, analyst optimism, and growth in travel demand. Key risks include high debt levels, with debt-to-asset ratio rising to 73.88% in 2025, and sensitivity to economic cycles affecting travel spending. The stock offers potential upside to the consensus target, but investors should monitor debt management and macroeconomic conditions.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
